Since the last Annual Meeting, we have witnessed another dramatic wave of progress against cancer, from exciting basic science findings, to new drug approvals, expanded use of genomic data for precision medicine, and a greater focus on “big data” to accelerate progress in cancer research and in the clinic. Scientists are harnessing the power of mathematics, engineering, and artificial intelligence to diagnose cancer at an earlier stage. They are also concentrating their efforts on cancer in minorities and the medically underserved, working to eliminate the persistent disparities in cancer outcomes. All of these developments are reflected in the theme for the upcoming AACR Annual Meeting: “Driving Innovative Cancer Science to Patient Care.” This theme is a powerful reminder that at the heart of every scientific advance is a patient in urgent need of a cure.
Presentations at the Annual Meeting will cover the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations. AACR will feature new sessions on cancer health disparities that have been inspired by one of the important AACR presidential initiatives. AACR will also be reprising a popular new feature from Annual Meeting 2017, “Unsolved Mysteries,” featuring provocative questions and in-depth discussion by speakers and members of the audience.
Charles River will present the following posters at this event:
April 15, 2018, 1:00-5:00 p.m.
- Immune checkpoint inhibitor induced tumor gene expression changes in murine syngeneic colon cancer models
Patrick Fadden, Douglas Weitzel, Kelli Davis, Thi Bui, David Hurtado, Hannah Haines, Rhiannon Roark, Ashleigh Derrick, Beverly Godfrey, Ian Belle, Katherine Krontz, Cristina Sokolowski, Aidan Synnott, Edgar Wood
- Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics
Partnered with InSphero
Francesca Chiovaro, Irina Agarkova, Armin Maier, Simon Messner, Julia Schueler, Patrick Guye
April 16, 2018, 8:00 a.m.-12:00 p.m.
- Identification of signal transduction pathway activity in patient-derived xenograft models in comparison with their originating clinical samples of a variety of human cancer types
Partnered with: Philips Research, Eindhoven, Netherlands
Wim Verhaegh, Anja van de Stolpe, Nevisa Caushaj, Manuel Landesfeind, Angelika Zaremba
- A translational platform using primary human immune cells in vitro, syngeneic and humanized models in vivo to support and advance immune-oncology drug discovery
Shilina Roman, Julia Schueler, Martin O’Rourke, Edgar Wood, Gary Salmon, Ian Waddell
- Therapeutic response to PD1/PDL1 axis in a disseminated C1498 Syngeneic Tumor Model
Vivek Mahajan, Thi Bui, Ian Belle, Edgar Wood, Lindsay Usher, Elizabeth Rainbolt, Shasta Kidder, Aidan Synnott, David Harris
- Enhanced proliferation and effector functions of human immune cells in response to immune checkpoint therapy of MDA-MB-231 tumor bearing huNOG mice engrafted with human CD34+ cells
Thi Bui, Karyn McArtan Shinn, Emily G. O’Koren, Ashleigh Derrick, Beverly Godfrey, Ian Belle, Jason Davis, Aidan Synnott, Anya Avrutskaya,Paula L. Miliani de Marval
April 16, 2018, 1:00-5:00 p.m.
- Metastases of a Temozolomide sensitive patient derived melanoma xenograft model show distinct biological features and developed resistance against Temozolomide
Kerstin Klingner, Dorothee Lenhardt, Elke Simon, Anne-Lise Peille, Julia Schüler
April 17, 2018, 8:00 a.m.-12:00 p.m.
- Quantitative measurement of immune-modulatory mediators within tumors of freely moving mice utilizing in vivo microdialysis
Nadege Morisot, Julien Roeser, Hajo Schiewe, Holden Brown Janssens, Marieke van der Hart, Arash Rassoulpour
- Influence of targeted silencing of the BRCA1 gene on the pharmacological profile of the mouse breast cancer cell line EMT6 in vitro and in vivo
Anya Avrutskaya, Maycee Robinson, Cordula Tschuch, William Durham, Gerhard Kelter, Astrid Jensen, Armin Maier, Aidan Synnott, Anne-Marie Zuurmond, Julia Schüler
- Molecular, histopathologic, MRI and PET findings in syngeneic oncologic mouse models
Julia Schueler, Artem Shatillo, Jussi Rytkönen, Nina Zanella, Antti Nurmi, Tuulia Huhtala
April 17, 2018, 2:35-3:00 p.m.
- The single mouse trial: a preclinical platform feasible for drug screening, model characterization and translational biomarker development
April 17, 2018, 1:00-5:00 p.m.
- Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development
Partnered with Ocello
Sander Basten, Bram Herpers, Kuan Yan, Julia Schueler, Willemijn Vader, Leo Price
April 18, 2018, 8:00 a.m.-12:00 p.m.
- Perfusion air culture of tissue slices: A new method to cultivate tumor tissue with minimal culture-dependent tissue stress
Kathrin Boepple, Meng Dong, Emma Davis, Julia Schueler, Heike Walles, John Hickman, Walter E. Aulitzky, Heiko van der Kuip
- Characterization of tumor growth and immune microenvironment in humanized NOG-EXL mice implanted with A549, MDA-MB-436 and A375 cells
Srimoyee Ghosh, Anne Fiore, Christoph Eberle, Sarah Wang, Keith Mikule, Kristen McEachern, Sujatha Kumar, David Jenkins, Geeta Sharma
When you plan your agenda, be sure to visit us at booth #1615 to learn how our comprehensive, integrated portfolio of services can support your drug discovery and development programs from hit ID to IND. You can also set up a time to meet with our scientists. We're interested in learning more about your research and would love the chance to talk while at the meeting.
For more information on our participation at this event, please contact us at [email protected].